Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Blood Adv. 2022 Jan 25;6(2):368-372. doi: 10.1182/bloodadvances.2020003876.

Martina Zátopková^{1

2

3}, Tereza Ševčíková^{1

2

3}, Viola Fanfani⁴, Zuzana Chyra^{1

2

5}, Lucie Říhová⁶, Renata Bezděková⁶, David Žihala^{1

2

3}, Kateřina Growková^{1

2

3}, Jana Filipová¹, Lucie Černá¹, Lucie Broskevičova², Fedor Kryukov⁷, Jiří Minařík⁸, Jana Smejkalová², Vladimír Maisnar⁹, Ĺubica Harvanová¹⁰, Luděk Pour¹¹, Alexandra Jungova¹², Tereza Popková², Juli Rodriguez Bago^{1

2}, Anjana Anilkumar Sithara^{1

2}, Matouš Hrdinka^{1

2}, Tomáš Jelínek^{1

2

3}, Michal Šimíček^{1

2

3}, Giovanni Stracquadanio⁴, Roman Hájek^{1

2}

¹ Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
² Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
³ Department of Biology and Ecology, University of Ostrava, Ostrava, Czech Republic.
⁴ Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh, United Kingdom.
⁵ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
⁶ Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
⁷ Clinical Development Department, Joint-stock Company BIOCAD, Saint Petersburg, Russia.
⁸ Department of Hematooncology, University Hospital and Palacky University Olomouc, Olomouc, Czech Republic.
⁹ 4th Department of Medicine-Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
¹⁰ Department of Hematology and Transfusiology, University Hospital Bratislava, Bratislava, Slovakia.
¹¹ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; and.
¹² Department of Hemato-Oncology, Charles University Hospital Pilsen, Pilsen, Czech Republic.

No abstract available

Publication types